Whereas tumors harboring the control shRNA showed the expected reduction in tumor burden (Fig. 4a,b) and fraction of Ki67+ cells (Fig. 4c,d) following Smad4 reactivation, the p57-depleted tumors did not. Here, SMAD4 is linked to neoplasm.